IL17A and psoriasis vulgaris: The efficacy and safety results with monoclonal antibodies targeting IL‐17RA (brodalumab) and IL‐17A (ixekizumab and secukinumab) validate IL‐17 as an effective therapeutic target for the treatment of plaque psoriasis.2